Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

• Status: Completed
• Trial end date: 2019-07-08
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy and radiotherapy in breast cancer patients after breast surgery.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Treatments: Carboplatin

Criteria

Inclusion Criteria:

• Age older than 18

• Pre- or post-menopausal women with Stage I and II breast cancer, triple negative tumors

• Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm

• Status post segmental mastectomy, after sentinel node biopsy and/or axillary node dissection (Tumors < 5 mm in size do not require nodal assessment) or after mastectomy

• No previous chemotherapy

• Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document

Exclusion Criteria:

• Previous radiation therapy to the ipsilateral breast

• Active connective tissue disorders, such as lupus or scleroderma

• Pregnant or lactating women